Intestine-derived sorbitol drives steatotic liver disease in the absence of gut bacteria
Science Signaling · 28.10.2025 · 18 (910)
DOI: 10.1126/scisignal.adt3549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, erschienen am 28.10.2025. Verfasst von Madelyn M Jackstadt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63130, USA. Hauptthemen laut MEDLINE: Fatty Liver, Gastrointestinal Microbiome, Sorbitol. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
Metabolic dysfunction–associated steatotic liver disease (MASLD) is linked to a shift in the composition of the gut microbiome. Here, we found that depletion of the gut microbiome in adult zebrafish led to the development of steatotic liver disease in animals on standard diets. Using metabolomics and isotope tracing, we found that dietary glucose was converted to sorbitol by host intestinal cells. Although bacteria degraded sorbitol in control animals, sorbitol was transferred to the livers of fish when the gut microbiome had been depleted. Within the liver, sorbitol was converted into fructose 1-phosphate, which subsequently activated glucokinase and increased glycolytic flux, leading to increased hepatic glycogen and fat content. Inhibition of sorbitol production in microbiome-depleted animals was sufficient to prevent the development of steatotic liver, and colonizing the intestines of microbiome-depleted fish with sorbitol-degrading Aeromonas bacterial strains rescued the steatotic liver phenotype. Conversely, exogenous administration of high concentrations of sorbitol phenocopied gut microbiota depletion and induced hepatic steatosis. Together, these findings show that sorbitol-degrading bacteria in the gut protect against steatotic liver disease and suggest that excessive intake of dietary sorbitol may pose a risk for the development of MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Washington University in St. Louis, St. Louis, MO 63130, USA.
- Department of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA.
- Center for Mass Spectrometry and Metabolic Tracing, Washington University in St. Louis, St. Louis, MO 63130, USA.
- Center for Human Nutrition, Washington University in St. Louis, St. Louis, MO 63110, USA.
- Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, USA.
ORCID-Profile: Madelyn M Jackstadt, Ronald Fowle-Grider, Matthew H Ward, Madison Barr, Kevin Cho, Hector H Palacios, Samuel Klein, Leah P Shriver, Gary J Patti
Förderung
- NIDDK NIH HHS
- NIEHS NIH HHS
Zitieren
APA
Jackstadt, M. M., Fowle-Grider, R., Song, M. G., Ward, M. H., Barr, M., Cho, K., Palacios, H. H., Klein, S., Shriver, L. P., & Patti, G. J. (2025). Intestine-derived sorbitol drives steatotic liver disease in the absence of gut bacteria. Science Signaling, 18(910). https://doi.org/10.1126/scisignal.adt3549
Vancouver
Jackstadt MM, Fowle-Grider R, Song MG, Ward MH, Barr M, Cho K, et al. Intestine-derived sorbitol drives steatotic liver disease in the absence of gut bacteria. Science Signaling. 2025;18(910). doi:10.1126/scisignal.adt3549
BibTeX
@article{Jackstadt2025,
author = {Jackstadt, Madelyn M and Fowle-Grider, Ronald and Song, Mun-Gu and Ward, Matthew H and Barr, Madison and Cho, Kevin and Palacios, Hector H and Klein, Samuel and Shriver, Leah P and Patti, Gary J},
title = {Intestine-derived sorbitol drives steatotic liver disease in the absence of gut bacteria},
journal = {Science Signaling},
year = {2025},
volume = {18},
number = {910},
doi = {10.1126/scisignal.adt3549}
}
EUVIMED